Instead of covering every Depo-Provera risk, this article focuses tightly on meningioma—what it is, how it has been linked to injections, and what kinds of evidence lawyers look for when connecting a tumor diagnosis to past Depo-Provera use.
Recent scientific research has revealed a concerning connection between Depo-Provera injections and the development of meningiomas, tumors that form on the protective layers surrounding the brain and spinal cord. A landmark French study published in the BMJ found that women who used high-dose progestogen medications like Depo-Provera for extended periods faced a significantly elevated risk of developing meningiomas—in some cases, more than five times higher than non-users.
This discovery has raised important questions about the safety of long-term Depo-Provera use and has led to growing litigation as women who developed meningiomas after using the medication seek to understand their legal rights. Understanding the scientific evidence, the potential risks, and what this means for women who have used Depo-Provera can help you make informed decisions about your health and legal options.
Pharmaceutical products and medical research documents
What Are Meningiomas?
Meningiomas are tumors that form on the meninges, the protective layers surrounding the brain and spinal cord. While typically non-cancerous, they can cause serious symptoms as they grow and may require surgical intervention or other treatments. These tumors develop from cells in the meninges and can vary in size and location.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Common symptoms of meningiomas include persistent headaches, vision problems, hearing loss or ringing in ears, memory difficulties, seizures, weakness in limbs, and personality changes. The severity of symptoms often depends on the size and location of the tumor, with some meningiomas causing no symptoms while others can lead to significant neurological problems.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationMeningiomas are the most common type of primary brain tumor, accounting for approximately one-third of all brain tumors. While most are benign, they can still cause serious health issues depending on their location and size. Treatment options may include monitoring, surgery, radiation therapy, or a combination of approaches depending on the individual case.
The Scientific Research Linking Depo-Provera to Meningiomas
The connection between Depo-Provera injections and meningiomas emerged from a comprehensive French study published in the BMJ. This research examined the medical records of thousands of women and found a significant association between long-term use of high-dose progestogen medications, including Depo-Provera, and the development of meningiomas.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The study found that women who used Depo-Provera for extended periods faced substantially higher risks of developing meningiomas compared to women who did not use the medication. The risk increased with the duration of use, with women who used the medication for five or more years facing significantly higher risks than those who used it for shorter periods.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
The research suggests that the hormone medroxyprogesterone acetate, the active ingredient in Depo-Provera, may play a role in the development of these tumors. While the exact mechanism is still being studied, the evidence indicates a clear association between long-term Depo-Provera use and increased meningioma risk.
What Is Depo-Provera?
Depo-Provera is an injectable contraceptive medication that contains the hormone medroxyprogesterone acetate. The medication is administered as an injection every three months to prevent pregnancy. It has been used by millions of women worldwide since its approval by the FDA in 1992.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewThe medication works by preventing ovulation and thickening cervical mucus to block sperm. While effective for birth control, emerging research has raised concerns about potential long-term health risks, particularly related to brain tumor development. Many women have used Depo-Provera for extended periods, sometimes for years or even decades, which may have contributed to the increased risk observed in recent studies.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Depo-Provera injections are typically administered by healthcare providers into the muscle of the arm or buttock. Each injection releases the hormone slowly over time, maintaining contraceptive effectiveness for approximately 12 to 14 weeks. The cumulative exposure from repeated injections over many years may be a factor in the increased meningioma risk observed in long-term users.
Legal documents and research papers representing ongoing litigation
How Exposure Occurred
Women were exposed to Depo-Provera through regular injections administered by healthcare providers. The medication is typically injected into the muscle of the arm or buttock every 12 to 14 weeks. Each injection releases the hormone slowly over time, maintaining contraceptive effectiveness.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityExposure occurred through regular injections every three months, long-term use over multiple years, cumulative exposure building up over time, and direct injection into muscle tissue. Many women used Depo-Provera for extended periods, sometimes for years or even decades. This long-term, repeated exposure may have contributed to the increased risk of developing meningiomas observed in recent studies.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The cumulative nature of the exposure is particularly important, as the hormone builds up in the body over time with each injection. Women who received injections for many years may have had significantly higher cumulative exposure than those who used the medication for shorter periods, which may explain why the risk increases with duration of use.
Who May Be Affected
Women who used Depo-Provera for extended periods may be at increased risk of developing meningiomas. Research suggests that the risk increases with the duration of use. Women who used the medication for one to four years may face a moderate increase in risk, while those who used it for five or more years may face significantly higher risks. Women who used it for ten or more years may face the highest risks.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The French study found that women who used high-dose progestogen medications for more than a year had a significantly elevated risk, with some groups facing risks more than five times higher than non-users. Women who have been diagnosed with meningiomas after using Depo-Provera should consider having their situation evaluated to determine whether they may have a valid legal claim.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, you may want to learn more about Depo-Provera lawsuit information and your potential rights. See if you qualify for a free case review to determine whether you may have a valid claim.
Current Status of Litigation
Litigation related to Depo-Provera and meningiomas is developing as more women learn about the potential connection between their medication use and brain tumor diagnosis. Cases are being filed alleging that manufacturers knew about the risks but failed to adequately warn patients and healthcare providers.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitA 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The litigation is in early stages, with cases being filed in various courts. As more scientific evidence emerges and more women come forward, the litigation may develop into consolidated proceedings similar to other pharmaceutical mass tort cases. Scientific evidence continues to accumulate linking progestogen exposure to meningioma development. This evidence may support legal claims that manufacturers had an obligation to warn about these risks but failed to do so adequately.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Evidence suggests that the risks associated with progestogen exposure were known for years before adequate warnings were provided. Pharmaceutical companies have a legal obligation to warn patients and healthcare providers about known risks. If you've used Depo-Provera for an extended period and developed a meningioma, you may be entitled to compensation for medical expenses, lost wages, pain and suffering, future medical care, and reduced quality of life.
Evidence and documents in legal proceedings
What a Case Review Involves
A case review is an initial evaluation to determine whether you may have a valid legal claim related to Depo-Provera use and meningioma development. This process is confidential, free, and does not create any obligation on your part.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Initial Consultation: The process typically begins with a conversation about your Depo-Provera use history and medical diagnosis. You'll be asked about when you started using Depo-Provera, how long you used it, when you received your meningioma diagnosis, and what symptoms you've experienced.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Medical Records Review: If you decide to proceed, medical records related to your meningioma diagnosis and treatment may be reviewed. This helps establish the connection between your medication use and your condition. You may also be asked about your Depo-Provera injection history and any documentation you have.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Eligibility Assessment: Based on the information gathered, an assessment will be made about whether you may qualify to pursue a claim. Factors considered include the duration of your Depo-Provera use, the timing of your diagnosis, and how your case fits within the broader litigation.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityAccording to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Next Steps: If you may qualify, you'll be informed about the next steps in the legal process. This might include connecting you with an independent law firm that handles Depo-Provera cases. If you don't qualify, you'll receive an explanation of why.
No Upfront Costs: Case reviews are conducted at no cost to you. If you qualify and choose to proceed with a case, most attorneys work on a contingency fee basis, meaning they only receive payment if your case is successful. To understand more about how mass tort cases work, you may find our guide on understanding mass tort litigation helpful.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The case review process is designed to be straightforward and respectful of your situation. The goal is to help you understand your options and determine whether pursuing legal action makes sense for your circumstances. If you're ready to begin, you can contact us for a free case review.
Why timing and records matter
Pharmacy records, injection dates, and radiology reports anchor most screenings. Gather them before your consultation so attorneys spend time on strategy—not chasing basic documents.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationAccording to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Scientific Evidence: While research suggests a link between Depo-Provera and meningiomas, scientific evidence continues to evolve. Courts will evaluate this evidence, and outcomes may depend on how juries and judges interpret the available research.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Litigation Timeline: Mass tort litigation typically takes several years to resolve. Cases may proceed through discovery, expert witness preparation, and potentially trials or settlement negotiations. The timeline for your specific case depends on many factors beyond your control.
See if you qualify for a free case review to learn more about your potential rights and options. You can also learn more about Depo-Provera lawsuit information and your potential rights.
Important Disclaimers
The connection between Depo-Provera injections and meningiomas represents an important development in understanding the potential risks associated with long-term contraceptive use. If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, understanding your legal rights and options is an important first step.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitAccording to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Privacy matters: a case review through Top Tier Legal does not obligate you to hire anyone. You choose whether to sign with a referred firm after speaking with them.
Top Tier Legal, LLC is not a law firm and does not provide legal advice. This content is for informational purposes only. Submitting information does not create an attorney-client relationship. If you qualify, Top Tier Legal, LLC may connect you with an independent law firm. Past results do not guarantee future outcomes.
